| MORPHOSYS AG O.N. | 109.50 / -0.82% |
| Date/Time | 08/12 / 08:10 |
| Chg. / Chg.(%) | -0.90 / -0.82% |
| Bid | - |
| Ask | - |
| Open | 109.50 |
| Previous Close | 110.40 |
| High | 109.50 |
| Low | 109.50 |
| Volume [EUR] | 0.00 |
| Volume [Units] | 0 |
| Price fixings | 1 |
| ISIN | DE0006632003 |
| Security | MOR |
| Exchange | Hannover |
| Type | Stock |
Other Exchanges
| Exchange | Last | Volume | |
|---|---|---|---|
| SIX Swiss Ex.. | 102.00 |  |
253,307 |
| Xetra | 110.65 | |
97,123 |
| Cboe Europe .. | 110.65 | |
35,418 |
| London Inter.. | 110.15 | |
17,767 |
| Cboe Europe .. | 110.65 | |
10,228 |
| Turquoise | 110.65 | |
8,992 |
| TradeGate | 110.400 |  |
5,144 |
| Stuttgart | 110.400 | |
870 |
| Frankfurt | 109.6000 | |
450 |
| gettex | 110.500 | |
104 |
| Vienna Globa.. | 110.75 | |
0 |
| Hannover | 109.50 | |
0 |
| Berlin | 109.50 | |
0 |
| München | 109.00 | |
0 |
| Hamburg | 109.50 | |
0 |
| Düsseldorf | 109.55 | |
0 |
| Lang & Schwa.. | 110.150 | |
|
| Nasdaq Other.. | 125.9600 | 50,900 | |
| EUREX | Options | ||
News
- I-Mab and MorphoSys Announce First Patient Dosed in Phase 3 Clinical Trial of TJ202/MOR202 in r/r Multiple Myeloma in Mainland China
04/27/2020 / 22:01 - GlobeNewswire - MOR106 clinical development in atopic dermatitis stopped for futility
10/28/2019 / 21:45 - GlobeNewswire - Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis patients
04/23/2019 / 22:02 - GlobeNewswire - Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis patients
04/23/2019 / 22:01 - GlobeNewswire - Genmab Announces that the Patent Infringement Lawsuit Relating to DARZALEX® is Over
01/31/2019 / 13:36 - GlobeNewswire
Real-time